2 results

  • cimerli

    (ranibizumab-eqrn)
    Coherus BioSciences Inc
    CIMERLI is indicated for treating neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.

  • yusimry

    (adalimumab-aqvh)
    Coherus BioSciences Inc
    YUSIMRY is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis. It helps reduce symptoms, improve function, and inhibit structural damage in these conditions.